The transition from a fasted to a fed state is associated with extensive transcriptional remodeling in hepatocytes facilitated by hormonal- and nutritional-regulated transcription factors. Here, we use a liver-specific glucocorticoid receptor (GR) knockout (L-GRKO) model to investigate the temporal hepatic expression of GR target genes in response to feeding. Interestingly, in addition to the well-described fasting-regulated genes, we identify a subset of hepatic feeding-induced genes that requires GR for full expression. This includes Gck, which is important for hepatic glucose uptake, utilization, and storage. We show that insulin and glucocorticoids cooperatively regulate hepatic Gck expression in a direct GR-dependent manner by a 4.6 kb upstream GR binding site operating as a Gck enhancer. L-GRKO blunts preprandial and early postprandial Gck expression, which ultimately affects early postprandial hepatic glucose uptake, phosphorylation, and glycogen storage. Thus, GR is positively involved in feeding-induced gene expression and important for postprandial glucose metabolism in the liver.
The nonselective beta blocker, propranolol, which for decades has been prescribed for treatment of cardiovascular conditions, has recently been used successfully to treat metastatic angiosarcoma. These results have led to an orphan drug designation by the European Medicines Agency for the treatment of soft tissue sarcomas. The anti-tumor effects of propranolol are suggested to involve the reduction of cancer cell proliferation as well as angiogenesis. Here, we have investigated the anti-angiogenic properties of propranolol in the context of stimulating an anti-tumor immune response. We show that oral administration of propranolol delays tumor progression of MCA205 fibrosarcoma tumors and increases the survival rate of tumor bearing mice. Propranolol works by reducing tumor angiogenesis and facilitating an anti-tumoral microenvironment with increased T cell infiltration and reduced infiltration of myeloid-derived suppressor cells (MDSCs). Using T cell deficient mice, we demonstrate that the full anti-tumor effect of propranolol requires the presence of T cells. Flow cytometry-based analysis and RNA sequencing of FACS-sorted cells show that propranolol-treatment leads to an upregulation of PD-L1 on tumor-associated macrophages (TAMs) and changes in their chemokine expression profile. Lastly, we observe that the co-administration of propranolol significantly enhances the efficacy of anti-CTLA4 therapy. Our results identify propranolol as an immune modulating agent, which can improve immune checkpoint inhibitor therapies in soft tissue sarcoma patients and potentially in other cancers.
Rhythmic gene expression is controlled by oscillating recruitment of specific transcription factors and co-regulators, including histone-modifying enzymes and chromatin-remodeling complexes. To unravel the significance of SWI/SNF ATPase subunits in diurnal chromatin remodeling, we have mapped diurnal chromatin accessibility, SWI/SNF occupancy, and gene expression throughout a day in the liver of male mice exposed to a night restricted feeding regimen. We find remarkable remodeling during fasting-to-fed transitions, and a third of rhythmic enhancers exhibited diurnal SWI/SNF occupancy and accessibility. Hepatocyte-specific disruption of either of the two mutually exclusive ATPases of SWI/SNF has minor effects on chromatin accessibility. However, simultaneous disruption of both ATPases results in a collapse of chromatin accessibility in the majority of distal cis-regulatory and a third of promoter proximal cis-regulatory elements, which leads to disrupted diurnal gene expression and signs of liver damage and inflammation. SWI/SNF-dependent promoters exhibit similarities with diurnal promoters, indicating a potential sequence-level bias that favors dynamic SWI/SNF-mediated chromatin remodeling. Collectively, this suggests an essential role of SWI/SNF-mediated chromatin remodeling of cis-regulatory regions for rhythmic gene expression and basic liver function.